Biosimilar Kanjinti Gets FDA Approval for Breast, Gastric Cancer
Kanjinti, a HER2/neu receptor antagonist, is indicated for adjuvant treatment of HER2-overexpressing node positive or node negative.
All articles by Diana Ernst, RPh
Keytruda Approved for First Line Treatment of Unresectable, Recurrent HNSCC
The FDA has approved Keytruda (pembrolizumab; Merck) for first line treatment of patients with metastatic or unresectable, recurrent head and neck squamous cell carcinoma as monotherapy for patients whose tumors express PD-L1 (Combined Positive Score [CPS] ≥1) or in combination with platinum and fluorouracil (FU) regardless of PD-L1 expression.
First-in-Class Treatment Approved for Advanced Breast Cancer
The FDA has approved Piqray (alpelisib; Novartis) in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endocrine-based regimen.
First Cancer Immunotherapy Regimen Approved for Breast Cancer Treatment
The Food and Drug Administration (FDA) has granted accelerated approval to Tecentriq (atezolizumab; Genentech) in combination with Abraxane.
Next post in Breast Cancer
